StocksMediumUpdated•Originally published 4 November 2026•Updated 4 November 2026•
1 min read
Myriad Genetics Stock Jumps 10.7% on Q3 Earnings Beat and Raised Guidance
Key Facts
1Myriad Genetics reported Q3 2026 revenue of $202.7 million, representing a 6% sequential increase.
2The company raised its full-year 2026 revenue guidance mid-point and announced a definitive agreement to sell its prenatal health business.
Myriad Genetics reported an adjusted loss per share of -$0.11 for the third quarter of 2026, beating consensus estimates by 44.9%. GlobeNewswire reported that revenue reached $202.7 million, a 6% sequential increase, triggering a 10.7% jump in the stock price following the release.
The company raised its full-year 2026 revenue guidance to a midpoint of $785 million while announcing a definitive agreement to divest its prenatal health business. Shares of MYGN closed at $6.04 on November 3, 2026, after trading between a session low of $5.85 and a high of $6.08.